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Pathobiology of
Troponin Elevations*
Do Elevations Occur With
Myocardial Ischemia as Well as Necrosis?
Harvey D. White, DSC
Auckland, New Zealand
Cardiac troponins are components of the contractual appa-
ratus in cardiac myocytes and are expressed exclusively in the
heart. A number of nonischemic conditions including myo-
carditis, pulmonary embolism, acute and chronic heart
failure, and sepsis may be associated with elevated troponin
levels (1,2), although they may include supply–demand
imbalance and thus at least some element of ischemia.
Elevation of troponins with these conditions is associated
with worse prognosis than the prognosis for patients with-
out troponin elevations, and the prognosis is usually worse
than that for patients with troponin elevation with acute
coronary syndromes (ACS) (3).
See page 2398
There has been a mantra that elevation of troponin levels,
no matter what the etiology, is always caused by myocyte
necrosis (4). This is supported by histological staining for
troponin in animal studies showing troponin T and I release
from cells was only associated with necrotic tissue (5). Yet,
we know that there are clinical situations where release of
troponins may occur without necrosis.
The introduction of more sensitive assays for troponins
means improved analytical sensitivity but decreased speci-
ficity (6,7). Low, but detectable, troponin levels are mea-
surable in normal people (8,9) with significant biological
variability (10).
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Approximately 5% to 8% of troponin I and T is unbound in
the cytosol (11) or as part of an early releasable pool (12).
This unbound pool of troponin is released first, regardless of
the cause of the type of myocyte injury (Table 1). It would
be expected that if there is release from this pool that the
troponin would be released quickly and that blood levels
would fall with rapid washout. The half-life of troponin T
and troponin I in the blood is about 2 h (13). Rapid rise and
fall within 24 h may therefore be consistent with release of
this pool and reversible myocyte damage rather than myo-
cyte necrosis where a time-dependent fall over a longer
period (4 to 10 days) would be expected because of gradual
degradation of myofibrils and release of the troponin com-
plex (11). The prolonged half-life seen in ACS may be due
to continued breakdown of the contractile proteins.
A number of studies have suggested that troponins may
be released from cardiac myocytes in situations other than
myocyte necrosis without the cell membranes being ne-
crotic. It is not known whether this process is active or
passive. It is very common clinically for patients to present
with supraventricular tachycardia without either ischemic
symptoms or electrocardiographic changes and to have
elevated troponin levels. These levels usually rise and fall
rapidly, and coronary angiography may be normal (14).
Pulmonary embolism may be another setting where there is
a troponin release profile that may indicate reversible trans-
membrane release of troponin from the early releasable pool
(15), in addition to some myocyte necrosis.
Troponin Release With Ischemia
In this issue of the Journal the study by Turer et al. (16),
valuated 19 patients who underwent diagnostic cardiac cath-
terization and rapid atrial pacing for 60 to 180 min with
easurement of myocardial lactate production and highly
ensitive cardiac troponin T (hs-cTnT) from the coronary
inus and the peripheral blood. The assay for troponin T fulfills
he international biochemical requirements for a 10% coeffi-
ient of variation (CV) below the 99th percentile of a reference
opulation (2,4) and supports the classification of this assay as
uideline acceptable (17). The experimental design has been
sed before and is valid; although it is notable that measure-
ent of lactate elution is relatively insensitive for ischemia. The
rial appears to have been well conducted. However, there are
everal findings and methodological aspects that merit critical
ttention.
The rationale as to why the lower limit of hs-cTnT was set
o 1.5 ng/l and not to 3.0 ng/l (limit of blank) is not clear. This
ould have increased the chance of finding a significant
oncentration difference between the patients with coronary
rtery disease (CAD) and no lactate production, those with
AD and lactate production, and those without CAD and no
actate production. Many hs-cTnT values were below the limit
f blank, and most values before and after rapid atrial pacing
ere below the 99th percentile (13 ng/l).
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creased after pacing and tended to be higher in patients with
lactate production and CAD. However, levels also increased
in patients without lactate production and without CAD,
and the absolute changes were similar to those with lactate
production and CAD.
Lactate and the transcoronary lactate extraction was
measured but is not fully presented in the results. The only
statement is that transcoronary lactate extraction was 0.36
mg/dl at rest and 0.25 mg/dl at peak stress with a negative
value indicating myocardial ischemia. It would have been
nice to see a display of the association between troponin rise
and transcoronary lactate extraction with regression analysis
to support their conclusion.
The peak value of hs-cTnT did not exceed the upper
limit of normal (14 pg/ml) in any of the patients who did
not develop ischemia on an electrocardiogram or produce
lactate. This finding is reassuring in respect to the proposed
cut points (14 ng/l) and delta change of 50% for the
diagnosis of myocardial infarction (7).
The conclusion of the authors that the rise in hs-cTnT levels
is due to myocardial ischemia is not consistently supported by
the study findings. The authors found a troponin rise even in
patients without CAD and without a lactate gradient, which
supports the hypothesis that tachycardia alone may account for
troponin release. Troponin release may be mediated by tachy-
cardia stimulating stretch-responsive integrins, which are
mechanotransducer molecules that link the extracellular matrix
to the intracellular cytoskeleton (18). Also, there remains the
possibility that 60 min of pacing produced myocyte necrosis of
a small number of cells without lactate production as measured
in this study. Therefore, the conclusion that ischemia alone
caused the increase in hs-cTnT levels is not fully substantiated
by the study findings.
In patients undergoing stress testing with nuclear imag-
ing, low levels of troponin elevations were detected with the
ultrasensitive Singulex TnI assay (Singulex, Alameda, Cal-
ifornia), which uses single-molecule detection technology,
suggesting the possibility that transient provoked ischemia
can produce troponin release in the absence of necrosis (19).
The increases in troponin levels were associated with the
presence and severity of nuclear perfusion defects. These
data are different from a previous study where hs-cTnT did
not increase after brief exercise or pharmacologically in-
duced myocardial ischemia (20). Using a novel nanoparticle
Pathobiological Classification of Types ofo ential Mechanisms C usi g Tro onin ElevationsTable 1 P thobiological Classificati n of Type ofPotential Mechanisms Causing Troponin Elevations
Type 1 Myocyte necrosis
Type 2 Apoptosis
Type 3 Normal myocyte turnover
Type 4 Cellular release of proteolytic troponin degradation products
Type 5 Increased cellular wall permeability
Type 6 Formation and release of membranous blebstroponin I assay, 82% of patients presenting with unstableangina, with a negative contemporary troponin I assay, had
an elevated nanoparticle troponin I level indicating that
myocardial injury was detectable in most patients with
ischemia and again raises the possibility that troponin may
be released during ischemia without necrosis occurring (21).
These studies, however, cannot distinguish between small
areas of myocyte necrosis, which may be better detected
with more precise assays, versus reversible myocyte injury
with troponin release from the early releasable pool through
a viable intact cellular mechanism. The precise mechanism
of this process is not defined.
Potential Mechanisms of Troponin Release
There are 6 potential major pathobiological mechanisms for
troponin elevations (Table 1).
Myocyte necrosis. Myocyte necrosis is the most common
mechanism, and under this rubric are ischemic, inflammatory,
infiltrative, direct trauma, and toxic causes including sepsis (1).
Apoptosis. A second cause is apoptosis, or programmed cell
death. Apoptosis with preserved membrane integrity is associ-
ated with activation of caspases that mediate the cleavage of
structural proteins that may lead to the release of troponin (22).
Normal myocyte cell turnover. A third type is normal
myocyte cell turnover. Study of the integration of carbon-14
into the DNA of myocardial cells, generated by nuclear
bomb testing, has shown that cardiac myocytes regenerate
(23). There is a decrease from 1% annual turnover at the age
of 25 to 0.45% at the age of 75 years with approximately
50% of cells exchanged during a normal life span. Whether
such low-grade turnover results in release of troponin to the
systemic circulation is unknown.
Cellular release of proteolytic troponin degradation
products. Another potential cause of troponin release (type 4),
without death of the cell and cellular membrane disruption,
is the cellular release of proteolytic troponin degradation
products (24,25). Thus, proteolysis to create small fragments
could allow these to pass through a cellular membrane with
normal membrane integrity. Only 15 min of mild ischemia has
been shown to cause development of troponin I degradation
products (26).
Increased cellular wall permeability. A fifth type is increased
permeability of the cell membrane without cell necrosis.
Reversible injury to the cardiac myocyte membrane allowing
permeability of troponins from the cytosol may occur due to
myocardial stretch, or ischemia. Simulation of stretch-
responsive integrins has been shown to result in release of
intact troponin from cultured viable cardiomyocytes (18) with-
out an increase in lactate production inferring that release may
occur without ischemia or necrosis. Also, in a rat model,
increasing pre-load has been shown to be associated with
release of troponin I, independent of ischemia (25).
Formation and release of membranous blebs. Active
secretion of vesicles (blebs) or membrane expression with
shedding has been hypothesized to be a mechanism to
enable troponin to be released from cardiac cells. This
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molecules can pass from intracellular to extracellular spaces
without necrosis occurring, by the formation of membra-
nous blebs during ischemia. These may be released into the
circulation without rupture of the plasma membrane. Cul-
tured cardiac myocytes have been shown to develop blebs
during anoxia and to release cytosolic enzymes without
undergoing necrosis (27), but there is little evidence sup-
porting this concept in man.
There are also likely to be unknown causes of troponin
elevations. It is not known as to why sepsis causes the release
of troponin from cardiac myocytes, although heat shock
proteins and tumor necrosis factor have been implicated
(28). It is thought that increased troponin levels with renal
failure are not related to decreased renal excretion (28), but
rather to toxic products, and supply and demand issues
probably also play a role. It is also possible that there are
low-grade reparative processes compensating for myocyte
loss due to various causes.
If we accept that troponin release occurred with rapid pacing
in the current study as a result of ischemia rather than necrosis,
then the question arises as to what process caused the release.
Whether troponins are released only with necrosis or with
ischemia alone, perhaps through a stretch mechanism, should
not prevent us using the higher sensitivity troponin assays,
which fulfill the international recommendations for perfor-
mance (17) and have been shown to be related to worse
prognosis (29). The challenge is how to best incorporate higher
sensitivity troponins into clinical practice.
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